James has more than 17 years of venture capital experience as well as three years of operational experience in life science companies. He joined Abingworth as CFO in 1998 where he handles finance and administration as well as investment matters, focusing on start-up companies. His directorships have included Avillion, Chroma Therapeutics, Clinical Designs and Syntaxin.
Previously James was CFO of Prolifix. He trained and qualified as a Chartered Accountant with KPMG and holds a degree in Biology with Chemistry from the University of Southampton.